

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**Equality impact assessment**

**HTG770 Leadless cardiac pacemaker  
implantation for bradyarrhythmias**

**Scoping**

**1 Have any potential equality issues been identified during the scoping process? If so, what are they?**

Age: the incidence of cardiac bradyarrhythmias (sick sinus syndrome and atrioventricular conduction abnormalities) increases with age as predisposing causes become more frequent.

Gender: Cardiac bradyarrhythmias affect men and women equally.

Disability: People with bradyarrhythmia are likely to be covered by the Equality Act if their condition has had a substantial adverse impact on normal day to day activities for over 12 months or is likely to do so.

Ethnicity: Rates of permanent pacemaker implantation are lower in South Asians residing in the UK, compared with Caucasians. This observation raises the possibility of lower inherent susceptibility to bradycardias in South Asians compared with Caucasians (Yuyun et al 2018).

No data available from standard IP sources on sexual orientation.

**2 Have any potential health inequality issues been identified during the scoping process? If so, what are they?**

No health inequality issues were identified during the scoping process.

- 3 What is the preliminary view as to what extent the committee needs to address the potential issues set out in questions 1 and 2?**

The potential equality issues will be noted by the committee and inform discussions where appropriate.

- 4 Has any change to the draft scope been agreed to highlight the potential issues set out in questions 1 and 2?**

No

- 5 Has the stakeholder list been updated as a result of additional equality or health inequality issues identified during the scoping process?**

No

**Approved by associate director:** Lizzy Latimer

**Date:** 17/01/2026

## **Draft guidance**

- 6 Have the potential equality issues identified during the scoping process been addressed by the committee? If so, how?**

No

- 7 Have the potential health inequality issues identified during the scoping process been addressed by the committee? If so, how?**

No health inequality issues were identified during the scoping process.

- 8 Have any other potential equality or health inequality issues been raised in the stakeholder submissions or the assessment report? If so, how has the committee addressed these?**

Two additional potential issues were identified. These have both been described in the equality considerations of the draft guidance.

- 9 Have any other potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No

- 10 Do the preliminary recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.

- 11 Has the committee made any reasonable adjustments for the equality issues identified in its recommendations? That is, any adjustments needed to remove or alleviate barriers to, or difficulties with, access needed to fulfil NICE's obligations to promote equality.**

No

- 12 Have the committee's considerations of equality and health inequality issues been described in the draft guidance? If so, where?**

Two potential issues have been described in the equality considerations of the draft guidance.

Approved by associate director: Lizzy Latimer

Date: 17/01/2026

## Final draft guidance

**13 Have any additional potential equality or health inequality issues been raised during consultation on the draft guidance? If so, how has the committee addressed these?**

No

**14 Have any additional potential equality or health inequality issues been identified by the committee? If so, how has the committee addressed these?**

No

**15 If the recommendations have changed after consultation, do the updated recommendations make it more difficult for a specific group to access the technology than other groups? If so, what are the barriers to, or difficulties with, access for this group?**

The recommendations have changed but do not impact access by any specific group to the technology. The recommendations were made more permissive.

**16 If the recommendations have changed after consultation, has the committee made any other reasonable adjustments for the equality issues identified in its recommendations? That is, any adjustments needed to remove or alleviate barriers to, or difficulties with, access needed to fulfil NICE's obligations to promote equality.**

The recommendations have changed but no adjustments were needed with access.

**17 Have the committee's considerations of equality and health inequality issues been described in the final draft guidance? If so, where?**

Two potential issues have been described in the equality considerations of the guidance.

**Approved by associate director:** Lizzy Latimer

**Date:** 17/01/2026